<DOC>
	<DOCNO>NCT00771680</DOCNO>
	<brief_summary>This study conduct Europe Asia . The aim observational study evaluate effectiveness incidence serious adverse reaction use Levemir® , NovoMix® and/or NovoRapid® subject type 2 diabetes use insulin previously normal clinical practice condition .</brief_summary>
	<brief_title>Observational Study Evaluate Effectiveness Safety Levemir® , NovoMix® 30 NovoRapid® Insulin naïve Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Any insulin näive type 2 diabetic patient able use drug judge investigator In accordance approve label</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>